Adrenomed closes EUR 22 million equity financing to accelerate development of Adrecizumab
Management Changes
02-Dec-2020 -
Adrenomed AG, the vascular integrity company, announced the successful closing of a EUR 22.2 million financing round.
EUR 22 million financing round
An internal series E venture round led by existing investors Wellington Partners and HBM Healthcare Investments raised EUR 22.2 million equity. This ...
Adrecizumab
financing
septic shock